RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
It is expected that RAD001 works in gastric cancer by inhibiting PI3K/AKT/mTOR pathway and
Hif1A (hypoxia inducible factor 1, alpha subunit), a key player in angiogenesis and the
growth of tumors like renal cell carcinoma.However, RAD001 alone looks not enough to control
gastric cancer. By the mechanisms above, RAD001 can show additive or synergistic effect in
combination with conventional chemotherapy. In this study, XELOX was selected as a
conventional combination chemotherapy because it was proven very active and safe in gastric
cancer. Combination of XELOX and RAD001 has been never tried for the treatment of cancer
patients yet. So, the optimal dose will be first determined in this phase I study